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Background. Blood-brain barrier (BBB) dysfunction may have a signiﬁcant role in the pathogenesis of Alzheimer’s disease
(AD). Modiﬁable factors associated with BBB function may have therapeutic implication. This study tested the hypothesis that
dyslipidemia is associated with BBB impairment in mild-to-moderate AD. Methods. Thirty-six subjects with AD were followed
for 1 year. Fasting CSF and plasma were collected with clinical assessments at baseline and 12 months. BBB impairment was
deﬁned as CSF albumin index ≥9. Independent t-tests and linear regression assessed the relationship between plasma lipoproteins
and BBB integrity. Results. Dyslipidemia was prevalent in 47% of the population, and in 75% of those with BBB impairment.
Subjects with BBB impairment had signiﬁcantly higher mean plasma triglyceride and lower HDL cholesterol (TG, P = 0.007;
HDL, P = 0.043). Plasma triglycerides explained 22% of the variance in BBB integrity and remained signiﬁcant after controlling
for age, gender, ApoE-4 genotype, blood pressure, and statin use. Conclusion. Dyslipidemia is more prevalent in AD subjects with
BBB impairment. Plasma triglyceride and HDL cholesterol may have a role in maintaining BBB integrity in mild-to-moderate
Alzheimer’s disease.
1.Introduction
The CSF albumin index is an established measure of blood-
brainbarrier(BBB)integrityinlivingpatients[1].Thisindex
has detected a higher prevalence of BBB impairment in late
onset dementia, including both Alzheimer’s disease (AD)
and vascular dementia compared to cognitively intact elders
[2]. BBB impairment is associated with more rapid rate of
decline in AD over 1 year [3]. Capillary endothelia dysfunc-
tion and the approximate tight junctions between these cells
may be important to AD pathogenesis, including eﬀects on
maintaining cerebral perfusion and the clearance of toxic
forms of beta-amyloid protein [4, 5]. The notion that the
BBB is central to the pathogenesis of AD is controversial, but
the enormity of the cerebrovascular tree and the similarity in
risk factors between vascular and Alzheimer’s disease makes
the BBB and neurovascular unit diﬃcult to disregard [6, 7].
If BBB function plays a role in the pathogenesis of AD,
thenmodiﬁablefactorsassociatedwithitmayhavetherapeu-
tic potential. A clinical trial of B vitamin supplementation
has suggested that the BBB may be a modiﬁable entity in
subjects with hyperhomocysteinemia and mild cognitive im-
pairment [8]. Lipids are plausible candidates for modifying
BBB function because of their relationship with vascular
disease and ability to aﬀect AD type pathology [9]. This
study examines the relationship between dyslipidemia and
BBB integrity in a well-characterized sample with mild-to-
moderate Alzheimer’s disease.
2. Methods
2.1. Study Population. The study participants were recruited
from the clinic population of the NIA—Layton Aging and
Alzheimer’s Disease Center of Oregon Health and Science2 Current Gerontology and Geriatrics Research
Table 1: Study population characteristics1.
Total (n = 36) BBB intact (n = 28) BBB impaired (n = 8)
Age, years 70 (7.1) 70 (7) 73 (8)
Female, no. (%) 12 (33) 11 (39) 1 (13)
ApoE-e4 allele carriers (%) 27 (75) 21 (75) 6 (75)
BMI (%) 27 (4.6) 26 (4) 29 (6)
BP, systole, mmHg 142 (23.2) 143 (21) 137 (30)
BP, diastole, mmHg 78 (12.2) 79 (13) 76 (8)
Mini mental state exam 19 (5.0) 20 (5) 18 (5)
Hachinski ischemia score 0.6 (0.9) 0.5 (0.8) 1.0 (1.3)
Statin use, no. (%) 8 (22) 5 (18) 3 (38)
Glucose, mg/dL 99 (18) 98 (18) 101 (17)
CSF albumin index 7.2 (3.7) 5.6 (1.7) 12.9 (3.3)abc
Atherogenic dyslipidemia, no. (%)2 15 (42) 9 (32) 6 (75)a
Metabolic dyslipidemia, no. (%)2 17 (47) 11 (39) 6 (75)a
Triglycerides, mg/dL 215 (132) 185 (86) 323 (204)ab
HDL cholesterol, mg/dL 48 (20) 52 (22) 35 (5)a
LDL cholesterol, mg/dL 129 (33) 132 (37) 120 (10)
Total cholesterol, mg/dL 216 (36) 218 (40) 210 (27)
BBB: blood-brain barrier, ApoE-e4: apolipoprotein E epsilon 4, BMI: body mass index, BP: blood pressure, HDL: high-density lipoprotein, LDL: low-density
lipoprotein.
1Mean and standard deviation provided unless stated otherwise; aP<0.05, abP<0.01, abcP<0.001.
2Atherogenic dyslipidemia: triglycerides ≥ 150mg/dL, LDL > 100mg/dL and HDL < 50mg/dL [15].
3Metabolic dyslipidemia: triglycerides ≥ 150mg/dL, HDL < 50mg/dL [16].
University and have been described previously [3]. Brieﬂy,
all subjects had a consensus diagnosis of probable AD using
the National Institute of Neurological and Communicative
Disorders and Stroke/Alzheimer’s Disease and Related Dis-
orders Association criteria and a Clinical Dementia Rating of
0.5 or 1 to establish disease stage of mild-to-moderate AD.
All participants provided informed consent in accord with
the Institutional Review Board for human study at Oregon
Health and Science University. All subjects had CSF and
bloodavailableforanalysis.Twenty-threeofthese36subjects
have come to brain autopsy, and in all autopsy cases the
clinical diagnosis of AD was conﬁrmed pathologically.
2.2. Data Collection and Analysis. Thirty-six subjects with
mild-to-moderate AD were evaluated by medical history,
neurologicalandgeneralexamination,theMini-MentalState
Examination (MMSE) [10], the Clinical Dementia Rating
scale (CDR) [11], the modiﬁed Hachinski ischemia score
[12], and the Geriatric Depression Scale [13]. Cerebrospinal
ﬂuidandperipheralbloodwerecollected,andbrainMRIwas
performed.
Lumbarpunctureswereperformedinthemorningunder
standardized conditions at L3 to L4 or L4 to L5 interspaces,
immediately aliquoted, and snap frozen at −70◦C until as-
sayed. These samples had normal cell count and glucose
levels, and the aliquots analyzed were matched sequentially
by draw to control for CSF content drift by sequence. A
CSF-to-serum ratio of albumin (CSF Albumin Index) ≥ 9.0
was considered BBB impairment. Reproducibility of the
CSF albumin index in AD over 1-year has been established
(intraclass correlation coeﬃcient = .96) [3]. Blood samples
collected at the same visit as CSF were analyzed for albumin,
glucose, triglycerides, total cholesterol, and high- and low-
density lipoproteins by standardized methods performed by
the Atherosclerosis Lipid Research Laboratory at Oregon
Health and Science University [14]. Laboratory staﬀ was
blind to all clinical covariates.
2.3. Statistical Analysis
2.3.1. Descriptive Analysis. Two sample t-tests compared the
mean diﬀerences in CSF albumin Index by subjects classiﬁed
asatherogenicdyslipidemia(triglycerides≥150mg/dL,HDL
cholesterol < 50mg/dL and LDL cholesterol > 100mg/dL
[15]) and metabolic dyslipidemia (the atherogenic proﬁle
without reference to LDL cholesterol) [16]. Mean diﬀerences
in each lipid were compared between subjects with and
without BBB impairment.
2.3.2. Primary Analysis. Multivariable linear regression
models were ﬁt to assess the relationship between lipids and
CSF albumin index by including potential confounders in-
cluding age, gender, ApoE-4 genotype, blood pressure, and
statin use. Alpha level for signiﬁcance was set at 0.05 (2-
tailed).
3. Results
Table 1 summarizes the study population. Blood-brain bar-
rier (BBB) impairment was prevalent in 22%. Frequency ofCurrent Gerontology and Geriatrics Research 3
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Figure 1: Relationship between plasma lipids and blood-brain barrier in subjects with AD. (a) Mean diﬀerence in TG = 137.89mg/dL,
P = 0.007. (b) Mean diﬀerence in HDL = 16.17mg/dL, P = 0.043. Standard error bars around the mean set at +/−1.0. (c) Horizontal
reference line separates the plots by subjects with (above) and without (below) BBB impairment. Vertical reference line indicates lipid risk
threshold.
statin use was similar between the groups with and without
BBB impairment (P for diﬀerence = 0.251). Total and LDL
cholesterol were not diﬀerent between the two groups (total
cholesterol, P = .619; LDL cholesterol, P = .355). However,
mean plasma triglycerides were higher and HDL cholesterol
lower in subjects with BBB impairment (mean diﬀerence in
TG = 137.89mg/dL, P = 0.007; mean diﬀerence in HDL =
16.17mg/dL, P = 0.043) (Figures 1(a) and 1(b)). Seventy-
ﬁve percent (6/8) with BBB impairment had plasma triglyc-
erides ≥150mg/dL (range 55–646mg/dL) compared to 57%
(16/28) in subjects with intact BBB (range 55–389mg/dL).
EveryonewithBBBimpairmenthadplasmaHDLcholesterol
below 50mg/dL (range 29–43) compared to 60% (17/28) in
subjects with intact BBB (range 23–106mg/dL).
3.1.DyslipidemiaandBBBImpairmentinAlzheimer’sDisease.
The overall prevalence of “atherogenic” and “metabolic”
dyslipidemia was 42% and 47%, respectively. The prevalence
of atherogenic dyslipidemia was more frequent in AD
subjects with BBB impairment than in subjects without
(75% versus 32% with intact BBB, P = 0.030, Table 1).
Metabolic dyslipidemia was also more prevalent in BBB
impaired (75% versus 39% with intact BBB, P = 0.048).
Subjects with atherogenic dyslipidemia (n = 15) had mean
CSF Albumin Index 2.69 units higher than those without
(n = 21) (P = .029). Subjects with metabolic dyslipidemia
(n = 17) had mean CSF Albumin Index 2.43 units higher
than those without (n = 19) (P = 0.48).
3.2. Lipids Associated with BBB Integrity in Alzheimer’s Dis-
ease. Linear regression analysis indicated that each 10mg/dL
increase in plasma triglyceride content was associated with
a 0.13 unit increase in CSF Albumin Index (P = 0.004)
(Figure 1(c)). Plasma triglycerides explained 22.5% of the
variation in BBB integrity. The association between plasma
triglycerides and CSF Albumin Index remained signiﬁcant in4 Current Gerontology and Geriatrics Research
multivariable regression analysis controlled for age, gender,
ApoE-4 carrier status, systolic blood pressure, and statin use
(P = 0.040). Total cholesterol, LDL cholesterol, and HDL
cholesterol were not associated with CSF Albumin Index in
the regression model (data not shown).
4. Conclusion
These ﬁndings demonstrate a higher prevalence of dyslipi-
demia in Alzheimer’s subjects with BBB impairment. Plasma
triglycerides and HDL cholesterol were the lipids most
associated with BBB integrity. Plasma triglycerides explain
the most variation in BBB integrity compared to HDL, LDL,
and total cholesterol.
A relationship between triglycerides and dementia has
been reported in one large study [17]. This group compared
the various lipid components contributing to dementia risk
but did not report data on BBB integrity. To our knowledge,
this is the ﬁrst study to report a signiﬁcant relationship
between dyslipidemia and BBB integrity in Alzheimer’s dis-
ease. While a causal relationship between plasma lipids and
BBB cannot be assumed, the most plausible explanation may
be that BBB integrity in AD detected by the CSF Albumin
Index is related to atherosclerosis and its risk factors. For
example, the omega 3 polyunsaturated fatty acids, eicos-
apentaenoic acid, and docosahexaenoic acid are associated
with both vascular disease and dementia risk and are known
to lower plasma triglyceride levels [18]. It is also plausible
that the eﬀect of dyslipidemia on the BBB is independent
of atherosclerosis. This has been observed in the case of
an inborn error of cholesterol metabolism with neurologic
complications, cerebrotendinous xanthomatosis [19].
Although sample size in this study is a limitation, we
believe that the study has particular strengths worth noting.
Sixty four percent of this study population has autopsy
conﬁrmed AD, and the entire sample had probable AD
conﬁrmed by consensus diagnosis. Another strength is the
stability of the CSF Albumin Index as a measure of BBB
integrity in living subjects [3] and the collection of fasting
blood for the analysis of plasma lipids. These attributes min-
imize both risk of exposure and outcome misclassiﬁcation
and therefore strengthen the validity of the study ﬁndings in
a limited sample.
The possibility that dyslipidemia is causally related to
BBB impairment may be clinically signiﬁcant since dyslipi-
demia is treatable. If this evidence is conﬁrmed in other pop-
ulations, then the next step may involve a lipid-modify-
ing strategy to modify the natural history of AD. While it
is true that statin therapy has been unsuccessful in altering
the course of AD, these current ﬁndings place emphasis
on modifying triglyceride and HDL cholesterol, ideally in
subjects selected on the basis of BBB impairment at baseline.
Perhaps a dietary pattern or supplementation with omega-3
PUFAs and niacin would oﬀer one strategy, since they favor-
ably modify triglyceride and HDL cholesterol metabolism,
respectively [20]. The emergence of imaging modalities for
the assessment of BBB integrity will make these types of
intervention more feasible.
Acknowledgments
This paper is supported by NIH/NCCAM AT004777 K23
(GLB), VA Advanced Research Development Award (JFQ),
and NIH/NIA AG08017 (JAK).
References
[1] H. Link and G. Tibbling, “Principles of albumin and IgG
analyses in neurological disorders. II. Relation of the con-
centration of the proteins in serum and cerebrospinal ﬂuid,”
Scandinavian Journal of Clinical and Laboratory Investigation,
vol. 37, no. 5, pp. 391–396, 1977.
[2] I. Skoog, A. Wallin, P. Fredman et al., “A population study
on blood-brain barrier function in 85-year-olds: relation to
Alzheimer’sdiseaseandvasculardementia,”Neurology,vol.50,
no. 4, pp. 966–971, 1998.
[ 3 ]G .L .B o w m a n ,J .A .K a y e ,M .M o o r e ,D .W a i c h u n a s ,N .E .
Carlson, and J. F. Quinn, “Blood-brain barrier impairment
in Alzheimer disease: stability and functional signiﬁcance,”
Neurology, vol. 68, no. 21, pp. 1809–1814, 2007.
[4] R. D. Bell and B. V. Zlokovic, “Neurovascular mechanisms
and blood-brain barrier disorder in Alzheimer’s disease,” Acta
Neuropathologica, vol. 118, no. 1, pp. 103–113, 2009.
[5] B.V.Zlokovic,AnIntroductiontotheBlood-BrainBarrier,CR C
Press, Boca Raton, Fla, USA, 1993.
[6] D. J. Begley and M. W. Brightman, “Structural and functional
aspects of the blood-brain barrier,” Progress in Drug Research,
vol. 61, pp. 39–78, 2003.
[7] J .C.delaT orr e,“I sAlzheimer’ sdiseaseaneur odegenerativ eor
a vascular disorder? Data, dogma, and dialectics,” The Lancet
Neurology, vol. 3, no. 3, pp. 184–190, 2004.
[8] M. Lehmann, B. Regland, K. Blennow, and C. G. Gottfries,
“Vitamin B12-B6-folate treatment improves blood-brain bar-
rier function in patients with hyperhomocysteinaemia and
mild cognitive impairment,” Dementia and Geriatric Cognitive
Disorders, vol. 16, no. 3, pp. 145–150, 2003.
[9] L. M. Refolo, M. A. Pappolla, B. Malester et al., “Hypercholes-
terolemia accelerates the Alzheimer’s amyloid pathology in a
transgenic mouse model,” Neurobiology of Disease, vol. 7, no.
4, pp. 321–331, 2000.
[10] M.F.Folstein,S.E.Folstein,andP.R.McHugh,“‘Mini-mental
state’. A practical method for grading the cognitive state of
patients for the clinician,” Journal of Psychiatric Research, vol.
12, no. 3, pp. 189–198, 1975.
[11] G. Dooneief, K. Marder, M. X. Tang, and Y. Stern, “The
clinical dementia rating scale: community-based validation of
“profound’ and “terminal’ stages,” Neurology, vol. 46, no. 6,
pp. 1746–1749, 1996.
[12] J. T. Moroney, E. Bagiella, D. W. Desmond et al., “Meta-
analysis of the Hachinski ischemic score in pathologically
veriﬁed dementias,” Neurology, vol. 49, no. 4, pp. 1096–1105,
1997.
[13] J. A. Yesavage, T. L. Brink, and T. L. Rose, “Development and
validation of a geriatric depression screening scale: a prelimi-
nary report,” Journal of Psychiatric Research, vol. 17, no. 1, pp.
37–49, 1982.
[14] Lipid Research Clinics Program, Manual of Laboratory Oper-
ations, Lipid and Lipoprotein Analysis, Edited by Resources
DoHaH, National Heart, Lung and Blood Institute, Bethesda,
Md, USA, 1982.
[15] “Third report of the National Cholesterol Education Program
(NCEP) expert panel on detection, evaluation, and treatmentCurrent Gerontology and Geriatrics Research 5
of high blood cholesterol in adults (Adult Treatment Panel
III) ﬁnal report,” Circulation, vol. 106, no. 25, pp. 3143–3421,
2002.
[16] S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis
and management of the metabolic syndrome: an American
Heart Association/National Heart, Lung, and Blood Institute
scientiﬁc statement,” Circulation, vol. 112, no. 17, pp. 2735–
2752, 2005.
[17] C. Raﬀaitin, H. Gin, J. P. Empana et al., “Metabolic syndrome
and risk for incident Alzheimer’s disease orvascular dementia:
the Three-City study,” Diabetes Care, vol. 32, no. 1, pp. 169–
174, 2009.
[18] D. Mozaﬀarian and J. H. Wu, “Omega-3 fatty acids and
cardiovascular disease: eﬀects on risk factors, molecular path-
ways, and clinical events,” Journal of the American College of
Cardiology, vol. 58, no. 20, pp. 2047–2067, 2011.
[19] G. Salen, V. Berginer, and V. Shore, “Increased concentrations
of cholestanol and apolipoprotein B in the cerebrospinal ﬂuid
of patients with cerebrotendinous xanthomatosis. Eﬀect of
chenodeoxycholic acid,” The New England Journal of Medicine,
vol. 316, no. 20, pp. 1233–1238, 1987.
[20] S. Lamon-Fava, M. R. Diﬀenderfer, P. H. Barrett et al.,
“Extended-release niacin alters the metabolism of plasma
apolipoprotein (Apo) A-I and ApoB-containing lipoproteins,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no.
9, pp. 1672–1678, 2008.